Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;11(1):639-647.
doi: 10.1080/22221751.2022.2025746.

Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study

Jingwen Ai  1 , Yi Zhang  1 , Haocheng Zhang  1 , Qiran Zhang  1 , Zhangfan Fu  1 , Ke Lin  1 , Jieyu Song  1 , Yuanhan Zhao  1 , Mingxiang Fan  1 , Hongyu Wang  1 , Yang Zhou  1 , Xiaohua Chen  2 , Chao Qiu  1 , Wenhong Zhang  1   3   4
Affiliations

Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study

Jingwen Ai et al. Emerg Microbes Infect. 2022 Dec.

Abstract

A COVID-19 booster vaccination is being comprehensively evaluated globally due to the emerging concern of reduced protection rate of previous vaccination and circulating Variants of Concern (VOC). But the safety and immunogenicity of homologous BBIBP-CorV boosting vaccination are yet to be thoroughly evaluated. We conducted this prospective, open-label study in Huashan Hospital using a third 6.5U BBIBP-CorV administered at an interval of 4-8 months following the previous two doses in healthy adults. Safety, anti-RBD response and neutralizing titers against SARS-CoV-2 and VOCs were examined. Sixty-three and forty participants entered the booster and the control group, respectively. A significant increase in IFN-γ SFU per million PBMCs was observed on day 14 against N peptide (20 vs. 5, P < 0.001). On day 14, pVNT GMTs increased over 15 folds of the baseline levels against prototype to reach 404.54 titers and over 9-13 folds against 4 VOCs and continuously increased by day 28. sVNT GMTs increased 112.51 and 127.45 folds by days 14 and 28 compared to the baseline level. Median anti-RBD antibody and IgG level significantly increased from 11.12 to 2607.50 BAU/ml and 4.07 to 619.20 BAU/ml on day 14. On day 14, females showed a significantly higher cell-mediated immune response against S1 peptide. The 7-8 months interval group had a higher humoral response than the 4-6 months interval group. No severe adverse event was reported. A third homologous BBIBP-CorV boosting vaccination was safe and highly immunogenic for healthy adults and broadened participants' immunity against VOCs.

Keywords: SARS-CoV-2 inactivated vaccines; booster vaccination shot; homologous; immunogenicity; safety.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the authors.

Figures

Figure 1.
Figure 1.
The flowchart of the study.
Figure 2.
Figure 2.
Immune response after the third-dose vaccination. (a) IFN-γ SFU/million PBMCs after the third-dose vaccination. (b) Humoral immune responses against prototype and variants of SARS-CoV-2 after the third-dose vaccination evaluated by pVNT. (c) Humoral immune responses after the third-dose vaccination evaluated by sVNT. (d) Humoral immune responses after the third-dose vaccination evaluated by an anti-RBD antibody. (e) Humoral immune responses after the third-dose vaccination evaluated by anti-RBD IgG.
Figure 3.
Figure 3.
Impact of the interval among three doses of BBIBP-CorV vaccinations on humoral immune responses and T-cell response. (a) pVNT titer against prototype and variants of SARS-CoV-2 in participants administered with third doses at 4–6 months and 7–8 months intervals after second doses; (b) T-cell response in participants administered with third doses at 4–6 months and 7–8 months intervals after second doses.
See this image and copyright information in PMC

References

    1. See how vaccinations are going in your County and State 2021 [updated October 28]. Available from: https://www.nytimes.com/interactive/2020/us/covid-19-vaccine-doses.html.
    1. Zeng G, Wu Q, Pan H, et al. Immunogenicity and CoronaVac safety of a third dose of, and schedule immune persistence of a two-dose, healthy in adults: single-centre interim results from two, double-blind, randomised, phase placebo-controlled 2 Dis clinical trials. Lancet Infect. 2021. Dec 7;S1473-3099(21)00681-2. - PMC - PubMed
    1. Yorsaeng R, Suntronwong N, Phowatthanasathian H, et al. viral-vectored Immunogenicity of a third dose COVID-19 Vaccine vaccine after receiving two-dose inactivated vaccines in healthy adults.. 2022. Jan 24;40(3):524–530. - PMC - PubMed
    1. Pilishvili T, Gierke R, Fleming-Dutra KE, et al. . Effectiveness of mRNA COVID-19 vaccine among U.S. health care personnel. N Engl J Med. 2021. Dec 16;385(25):e90. - PMC - PubMed
    1. Chemaitelly H, Tang P, Hasan MR, et al. . Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021. Dec 9;385(24):e83. - PMC - PubMed

Substances